SCHEMBL24829674

SCHEMBL24829674

CN1c2ccccc2S(C)(C)c2ccccc21

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 2/20 0.48
CA9 Q16790 2/20 0.48
CA12 O43570 1/20 0.48
CA1 P00915 1/20 0.48
CA4 P22748 1/20 0.48
CA7 P43166 1/20 0.48
MAOA P21397 2/20 0.44
TP53 P04637 2/20 0.41
TTR P02766 1/20 0.35
CES1 P23141 1/20 0.35
ADRA2C P18825 3/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
ADRA2A P08913 2/20 0.33
ADRA2B P18089 2/20 0.33
SLC6A2 P23975 2/20 0.33
HTR2C P28335 2/20 0.33
SLC6A4 P31645 2/20 0.33
HTR2B P41595 2/20 0.33
MEN1 O00255 1/20 0.33
CHRM3 P20309 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2494216 0.78 MAOA (0.58) CA2CA9CA12CA1CA4
SCHEMBL26462842 0.78 CA12 (0.34) CA2CA9CA12CA1CA4
SCHEMBL25474345 0.78 CA12 (0.43) CA2CA9CA12CA1CA4
SCHEMBL19382933 0.75 ALDH1A1 (0.38) CA2CA9CA12CA1CA4
SCHEMBL25472129 0.75 CA9 (0.44) CA2CA9CA12CA1CA4
SCHEMBL19041842 0.75 CA12 (0.32) CA2CA9CA12CA1CA4
SCHEMBL24703560 0.75 SMN1; SMN2 (0.34) CA2CA9CA12CA1CA4
SCHEMBL25473004 0.75 CA2 (0.44) CA2CA9CA12CA1CA4
SCHEMBL4571020 0.74 MAOA (0.60) CA2CA9CA12CA1CA4
SCHEMBL13636983 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025878-A1 MDM2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-01-25 US disclosed
US-20230322831-A1 LIGHT-EMITTING DEVICE INCLUDING ORGANOMETALLIC COMPOUND, ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE, AND THE ORGANOMETALLIC COMPOUND SAMSUNG DISPLAY CO., LTD. (KR) 2023-10-12 US disclosed
US-20230137446-A1 THERMALLY ACTIVATED DELAYED FLUORESCENT MATERIAL, PREPARING METHOD THEREOF, AND ORGANIC ELECTROLUMINESCENT DEVICE WUHAN CHINA STAR OPTOELECTRONICS SEMICONDUCTOR DISPLAY TECHNOLOGY CO., LTD. (CN) 2023-05-04 US disclosed
US-20230137446-A1 THERMALLY ACTIVATED DELAYED FLUORESCENT MATERIAL, PREPARING METHOD THEREOF, AND ORGANIC ELECTROLUMINESCENT DEVICE WUHAN CHINA STAR OPTOELECTRONICS SEMICONDUCTOR DISPLAY TECHNOLOGY CO., LTD. (CN) 2023-05-04 US disclosed
US-11545638-B2 Organic compound and manufacturing method thereof, and organic light emitting diode electroluminescent device WUHAN CHINA STAR OPTOELECTRONICS SEMICONDUCTOR DISPLAY TECHNOLOGY CO., LTD. (CN) 2023-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240025878-A1 MDM2 DEGRADERS AND USES THEREOF MDM2, TP53, MDM4 CA2 4179/4885CA9 2559/4885CA12 2957/4885
US-20230322831-A1 LIGHT-EMITTING DEVICE INCLUDING ORGANOMETALLIC COMPOUND, ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE, AND THE ORGANOMETALLIC COMPOUND CRY1, LAGE3, LIG1 CA2 4308/4885CA9 3310/4885CA12 3559/4885
US-20230137446-A1 THERMALLY ACTIVATED DELAYED FLUORESCENT MATERIAL, PREPARING METHOD THEREOF, AND ORGANIC ELECTROLUMINESCENT DEVICE DNTT, CD69, DUT CA2 1534/4885CA9 1086/4885CA12 2209/4885
US-11545638-B2 Organic compound and manufacturing method thereof, and organic light emitting diode electroluminescent device HTT, ICMT, PORCN CA2 4784/4885CA9 4220/4885CA12 4860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.